Skip to content
value.today

Serimmune Inc.

Total raised
$15 M
2 rounds on record
Latest round
$12 M
Aug 2020
First round on record
Dec 2016
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Serimmune Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2020$12 MNo. 2$10 to $50 million

Serimmune Inc.: Raise no. 2, Aug 2020

Investors in this round

7 investors had bought by the notice of Sep 11, 2020: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $23 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jaymie R. Sawyer · Executive Officer
  • John M. Shon · Executive Officer
  • Noah Nasser · Executive Officer, Director
  • Patrick Daugherty · Executive Officer, Director
  • Stephen M. Kujawa · Executive Officer
  • Bill M. Welch · Director
  • Kristin M. Loomis · Director
  • Nicholas M. Naclerio · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Amount sold includes $6,649,673 of principal and interest on Notes which was converted to Series C Preferred Stock.”

Signed by Noah Nasser, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 11, 2020. Read the notice at the SEC.

equitySEC
Dec 2016$3 MNo. 1$2 to $10 million

Serimmune Inc.: Raise no. 1, Dec 2016

Investors in this round

7 investors had bought by the notice of Jan 5, 2017: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $8 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kristin Loomis · Executive Officer, Director
  • Patrick Daugherty · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Patrick Daugherty, Ceo. Source: SEC Form D, newest notice filed Jan 5, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Serimmune Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2020).

    SEC Form D · Sep 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2020

That is all the official record says: Serimmune Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Serimmune Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 7 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Serimmune Inc.
NameRoleNamed in
Jaymie R. SawyerExecutive officerSep 2020
John M. ShonExecutive officerSep 2020
Noah NasserExecutive officerSep 2020
Patrick DaughertyExecutive officerSep 2020
Stephen M. KujawaExecutive officerSep 2020
Kristin LoomisExecutive officerJan 2017
Bill M. WelchDirectorSep 2020
Kristin M. LoomisDirectorSep 2020
Nicholas M. NaclerioDirectorSep 2020
Noah NasserDirectorSep 2020
Patrick DaughertyDirectorSep 2020
Kristin LoomisDirectorJan 2017